IL6 and cancer: Further supporting the synergies of IL-6 blockade and ICB is the finding that inflammation induced by tumor-associated nerves promotes resistance to anti-PD1 therapy in cancer patients and is targetable by blockade of interleukin-6 [Baruch et al., 2023].